Pawe? Derejko, MD, PH D, a,b Jacek Kusnierz, MD,b Aleksander Bardyszewski, MD, b Dobromi?a Dzwonkowska, MD,b Magdalena Polanska-Skrzypczyk, MD, b ?ukasz Jan Szumowski, MD, P HD, a Atul Verma, MD
doi : 10.1016/j.jacep.2023.02.026
Volume 9, Issue 6, June 2023, Pages 733-737
Despite extensive conventional endoepicardial ablation, significant intramural arrhythmogenic substrate may remain out of reach of unipolar radiofrequency ablation (RFA).
Piotr Futyma, MD, PHD, a,b Piotr Ku?akowski, MD, PHD
doi : 10.1016/j.jacep.2023.05.012
Volume 9, Issue 6, June 2023, Pages 738-739
Marek Sramko, MD, PH D, a,b, * Saif Abdel-Kafi, MD,c,d, * Adrianus P. Wijnmaalen, MD, PH D, c,d Qian Tao, PH D, e Rob J. van der Geest, PH D, f Hildo J. Lamb, MD, PH D, g Katja Zeppenfeld, MD, P HD
doi : 10.1016/j.jacep.2022.10.035
Volume 9, Issue 6, June 2023, Pages 740-748
Electroanatomical voltage mapping (EAVM) has been compared with late gadolinium enhancement cardiovascular magnetic resonance (LGE-CMR), which cannot delineate diffuse fibrosis. T1-mapping CMR overcomes the limitations of LGE-CMR, but it has not been directly compared against EAVM.
Justin Hayase, MD, Jason Bradfield, MD
doi : 10.1016/j.jacep.2023.01.038
Volume 9, Issue 6, June 2023, Pages 749-750
Shiqin Yu, MD,a, * Xiuyu Chen, MD, P HD, a, * Zhixiang Dong, MD, a Huaibing Cheng, MD, PHD, b Kai Yang, MD, PH D, a Gang Yin, MM ED ,a Shujuan Yang, MD, a Wenhao Dong, BS, a Minjie Lu, MD, P HD, a Likun Ma, MD, PH D, c Shihua Zhao, MD, PHD a
doi : 10.1016/j.jacep.2022.12.012
Volume 9, Issue 6, June 2023, Pages 751-761
Benjamin Levin, MD, Charles A. Henrikson, MD
doi : 10.1016/j.jacep.2023.01.027
Volume 9, Issue 6, June 2023, Pages 762-764
J?lia Arany?, MD, a,b Daina Mart?nez-Falguera, BSC ,c,d V?ctor Bazan, MD, PHD, a,b Edgar Fadeuilhe, MD,a Albert Teis, MD,a,c,e Axel Sarrias, MD,a Oriol Rodr?guez-Leor, MD, PH D, a,e Carolina Curiel, BSC ,f Roger Villuendas, MD, PHD, a,e Antoni Bayés-Gen?s, MD, PH D, a,b,c,e,g Carolina G?lvez-Mont?n, DVM, PHD, a,c, * Felipe Bisbal, MD, PH D
doi : 10.1016/j.jacep.2022.11.023
Volume 9, Issue 6, June 2023, Pages 765-775
New tools are needed to improve ventricular tachycardia (VT) substrate characterization and optimize outcomes. LI provides biophysical tissue characterization.
Cory M. Tschabrunn, P HD, David J. Callans, MD
doi : 10.1016/j.jacep.2023.01.002
Volume 9, Issue 6, June 2023, Pages 776-778
Sara V?zquez-Calvo, MD, a,b Judit Mas Casanovas, BE NG ,a Paz Garre, BE NG, a,b Elisenda Ferr?, BE NG, a,b Paula S?nchez-Somonte, MD,a,b Levio Quinto, MD, a,b Eduard Guasch, MD, PHD, a,b,c Andreu Porta-Sanchez, MD, PH D, a,b José Maria Tolosana, MD, PHD, a,b,c Roger Borras, MS C, a,b Elena Arbelo, MD, P HD, a,b,c José T. Ortiz-Pérez, MD, PHD, a,b,c Josep Brugada, MD, PH D, a,b,c Llu?s Mont, MD, PHD, a,b,c Ivo Roca-Luque, MD, P HD
doi : 10.1016/j.jacep.2022.12.015
Volume 9, Issue 6, June 2023, Pages 779-789
A new functional mapping strategy based on targeting deceleration zones (DZs) has become one of the most commonly used strategies within the armamentarium of substrate-based ablation methods for ventricular tachycardia (VT) in patients with structural heart disease. The classic conduction channels detected by voltage mapping can be accurately determined by cardiac magnetic resonance (CMR).
Julian Mueller, MD,a,b,c Ivaylo Chakarov, MD, a Philipp Halbfass, MD,b,d Karin Nentwich, MD, a,b Elena Ene, MD,a Artur Berkovitz, MD,a Kai Sonne, MD, a Sebastian Barth, MD,a,b Christian Waechter, MD, b Michael Behnes, MD, c Ibrahim Akin, MD,c Stefan Fodor, MD, e Lukas Lehmkuhl, MD,e Thomas Deneke, MD
doi : 10.1016/j.jacep.2023.01.012
Volume 9, Issue 6, June 2023, Pages 790-804
Data about ventricular tachycardia (VT) ablation in patients with electrical storm (ES) is limited.
Neal A. Chatterjee, MD, MSC
doi : 10.1016/j.jacep.2023.03.012
Volume 9, Issue 6, June 2023, Pages 805-807
Michelle Samuel, MPH, PHD, a Jeff S. Healey, MD,b Isabelle Nault, MD,c Laurence D. Sterns, MD,d Vidal Essebag, MD, PH D, e,f Christopher Gray, MD, g Tomasz Hruczkowski, MD, h Martin Gardner, MD,g Ratika Parkash, MD,g John L. Sapp, MD
doi : 10.1016/j.jacep.2023.01.030
Volume 9, Issue 6, June 2023, Pages 808-821
Catheter ablation improves ventricular tachycardia (VT) event-free (time to event) survival in patients with antiarrhythmic drug (AAD)-refractory VT and previous myocardial infarction (MI). The effects of ablation on recurrent VT and implantable cardioverter-defibrillator (ICD) therapy (burden) have yet to be investigated.
Harikrishna Tandri, MD
doi : 10.1016/j.jacep.2023.05.017
Volume 9, Issue 6, June 2023, Pages 822-823
Justin Z. Lee, MD, a Min-Choon Tan, MD, a Suganya Karikalan, MBBS, a Abhishek J. Deshmukh, MD,a Komandoor Srivathsan, MD,a Win K. Shen, MD, a Hicham El-Masry, MD, a Luis Scott, MD,a Samuel J. Asirvatham, MD, b Yong-Mei Cha, MD, b Christopher J. McLeod, MBC HB, PHD, c Siva K. Mulpuru, MD
doi : 10.1016/j.jacep.2022.10.024
Volume 9, Issue 6, June 2023, Pages 824-832
Recognition of the causes of early mortality after ventricular tachycardia (VT) ablation in patients with reduced left ventricular ejection fraction (LVEF) is an essential step toward improving postprocedural outcomes.
Lars Eckardt, MD, PH D, a Stephan Willems, MD, P HD
doi : 10.1016/j.jacep.2022.11.004
Volume 9, Issue 6, June 2023, Pages 833-835
Andrea Radinovic, MD,a Giovanni Peretto, MD,a Giuseppe Sgarito, MD, P HD, b Filippo Maria Cauti, MD, c Antonello Castro, MD, d Maria Lucia Narducci, MD, PHD, e Roberto Mantovan, MD, f Marco Scaglione, MD,g Francesco Solimene, MD, h Alice Scopinaro, MD, i Claudio Tondo, MD, P HD, j Giulia Filippini, MD, k Elisabetta Bianco, MD,l Aldo Bonso, MD, m Vittorio Calzolari, MD,n Federico Ferraris, MD, o Marco Zardini, MD,p Marcello Piacenti, MD, q Giuseppe D’Angelo, MD,a Francesco Bosica, PHD, a Paolo Della Bella, MD
doi : 10.1016/j.jacep.2022.10.038
Volume 9, Issue 6, June 2023, Pages 836-847
Multicenter ventricular tachycardia (VT) ablation studies have shown poorer outcomes compared with single-center experiences. This difference could be related to heterogeneous mapping and ablation strategies.
Antonio Berruezo, MD, PHD, Giulio Falasconi, MD, Diego Penela, MD, PH D
doi : 10.1016/j.jacep.2022.12.013
Volume 9, Issue 6, June 2023, Pages 848-850
Edward J. Ciaccio, PH D, a,b James Coromilas, MD,c Elaine Y. Wan, MD,a Hirad Yarmohammadi, MD,a Deepak S. Saluja, MD, a Nicholas S. Peters, MD, P HD, b Hasan Garan, MD,a Angelo B. Biviano, MD
doi : 10.1016/j.jacep.2022.11.037
Volume 9, Issue 6, June 2023, Pages 851-861
Sinus rhythm electrical activation mapping can provide information regarding the ischemic re-entrant ventricular tachycardia (VT) circuit. The information gleaned may include the localization of sinus rhythm electrical discontinuities, which can be defined as arcs of disrupted electrical conduction with large activation time differences across the arc.
Joshua Hawson, MBBS,a,b Geoffrey Lee, MBC HB, PHD
doi : 10.1016/j.jacep.2022.12.023
Volume 9, Issue 6, June 2023, Pages 862-864
Gherardo Finocchiaro, MD, PhDy Raghav T. Bhatia, MBBSJoseph Westaby, MBBS, PhD Elijah R. Behr, MA, MBBS, MD Michael Papadakis, MBBS, MD Sanjay Sharma, BSc, MBChB, MD *Mary N. Sheppard, MBBCh, BAO, BSc, MD
doi : 10.1016/j.jacep.2022.12.007
Volume 9, Issue 6, June 2023, Pages 865-867
Federico Moccetti, MD Pedro Brugada, MD Gregorio Tersalvi, MD Mrinal Yadava, MD Yllka Latifi, MD Benjamin Berte, MD Richard Kobza, MD Christian Sticherling, MD *Tobias Reichlin, MD
doi : 10.1016/j.jacep.2022.12.017
Volume 9, Issue 6, June 2023, Pages 868-870
Maximilian S. Schaefer, MD, PhD Elena Ahrens, Cand Med Tracy Butler, MD
doi : 10.1016/j.jacep.2023.04.029
Volume 9, Issue 6, June 2023, Page 871
James K. Gabriels, MD Diana Anca, MD *Apoor Patel, MD yJim W. Cheung, MD
doi : 10.1016/j.jacep.2023.05.002
Volume 9, Issue 6, June 2023, Page 872
Kasun De Silva, MD, a,b Haris Haqqani, MBBS, PH D, c,d Rajiv Mahajan, MD, PH D, e Pierre Qian, MBBS, PHD, a,b William Chik, MBBS, PH D, a Aleksandr Voskoboinik, MBBS, PH D, f Peter M. Kistler, MBBS, P HD, f,g,h Geoffrey Lee, MBC HD, PH D, i Nicholas Jackson, MBBS,j,k Saurabh Kumar, MBBS, P HD
doi : 10.1016/j.jacep.2023.01.035
Volume 9, Issue 6, June 2023, Pages 873-885
There is variability in treatment modalities for premature ventricular complexes (PVCs), including use of antiarrhythmic drug (AAD) therapy or catheter ablation (CA). This study reviewed evidence comparing CA vs AADs for the treatment of PVCs.
Piotr Kulakowski, MD, P HD, a Pawel Derejko, MD, P HD, b,c Jacek Kusnierz, MD, P HD, b Jakub Baran, MD, P HD, a Urszula Hangiel, BS C, MPH, d Izabela Janus, MVD, PH D, e Agnieszka Noszczyk-Nowak, MVD, P HD
doi : 10.1016/j.jacep.2023.01.001
Volume 9, Issue 6, June 2023, Pages 886-888
Ruya Zhou, MD, Yifan Chen, MD, Xiaoyan Wu, MD, Xiang Mao, MD, Mengting Yang, MD, Jiafeng Lin, MD, Jia Li, MD, PH D
doi : 10.1016/j.jacep.2023.01.004
Volume 9, Issue 6, June 2023, Pages 889-891
Do you want to add Medilib to your home screen?